Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Study to Evaluate the Safety and Efficacy of AZD0486 in Adolescent and Adult Participants With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukaemia

NCT06137118 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT06137118
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06137118 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Study to Evaluate the Safety and Efficacy of AZD0486 in Adolescent and Adult Participants With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukaemia
Lead sponsor
AstraZeneca
Phase
Phase 1/2
Overall status
Recruiting
Start date
December 29, 2023
Completion date
August 10, 2028
Enrollment
255 (estimated)
Sites
83

Conditions

As the registry lists them; a condition with its own page is linked.

b-cell acute lymphoblastic leukemia (b-all)